Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide
Sanofi announced that starting January 1, 2026, no American will pay more than $35 per month for any of the company’s insulin products, with a valid prescription123.
The expanded Insulins Valyou Savings Program now covers all U.S. patients, regardless of insurance status—including those with commercial insurance, Medicare, and the uninsured12357.
The initiative addresses an affordability crisis in diabetes care, aiming to help millions of Americans living with diabetes, including the estimated 38.4 million diagnosed in the U.S.5.
Previously, the program only aided uninsured patients, but now extends to the entire U.S. market12357.
The program reflects Sanofi’s commitment to access and builds on earlier policy efforts to lower prescription costs for patients, with company representatives citing alignment with objectives first championed by President Trump123.
Sanofi will continue working with policymakers and stakeholders toward broader, sustainable solutions for drug access and healthcare affordability3.
Sources:
1. https://chaindrugreview.com/sanofi-caps-insulin-costs-at-35-nationwide/
2. https://investingnews.com/sanofi-expands-patient-affordability-program-by-offering-access-to-all-its-insulins-for-35-per-month-in-the-us/
3. https://www.prnewswire.com/news-releases/sanofi-expands-patient-affordability-program-by-offering-access-to-all-its-insulins-for-35-per-month-in-the-us-302567711.html
5. https://trial.medpath.com/news/49896c7e6d205c31/sanofi-expands-35-monthly-insulin-program-to-all-americans-regardless-of-insurance-status